Toggle Health Problems and D

1600 IU vitamin D safe for infants – RCT Nov 2102

High-Dose Vitamin D Intervention in Infants—Effects on Vitamin D Status, Calcium Homeostasis, and Bone Strength

The Journal of Clinical Endocrinology & Metabolism November 1, 2012 vol. 97 no. 11 4139-4147
Elisa Holmlund-Suila,
Heli Viljakainen,
Timo Hytinantti,
Christel Lamberg-Allardt,
Sture Andersson and
Outi Mäkitie
Children's Hospital (E.H.-S., H.V., S.A., O.M.), University of Helsinki and Helsinki University Central Hospital, 00029 Helsinki, Finland; Helsinki Maternity Hospital (T.H.), 00029 Helsinki, Finland; Calcium Research Unit (C.L.-A.), Department of Food and Environmental Sciences (Nutrition), University of Helsinki, 00014 Helsinki, Finland; and Folkhälsan Research Center (O.M.), 00014 Helsinki, Finland

Address all correspondence and requests for reprints to: Dr. Outi Mäkitie, Pediatric Endocrinology and Metabolic Bone Diseases, Children's Hospital, Helsinki University Central Hospital and University of Helsinki, P.O. Box 281, FIN-00029 HUS, Helsinki, Finland. E-mail: outi.makitie at helsinki.fi.

Context: Guidelines in Finland recommend 10 μg of vitamin D3 daily for all infants. Recent observations suggest that this may be insufficient to maintain optimal serum 25-hydroxyvitamin D (S-25-OHD).

Objective: The aim of the study was to evaluate effects of various vitamin D doses and determine a dose ensuring S-25-OHD of at least 80 nmol/liter in infants without signs of vitamin D excess.

Design: We conducted a randomized double-blind intervention study. Cord blood was obtained at birth for S-25-OHD; 113 infants were randomized to receive vitamin D3 10, 30, or 40 μg/d from age 2 wk to 3 months.

Setting: An investigator-initiated study was performed in a single maternity hospital in Helsinki, Finland.

Main Outcome Measures: S-25-OHD, calcium homeostasis, and skeletal characteristics were evaluated with peripheral quantitative computed tomography at age 3 months.

Results: Baseline S-25-OHD was similar in all three groups (median, 53 nmol/liter). At 3 months, the mean S-25-OHD values were 88, 124, and 153 nmol/liter, and the minimum values were 46, 57, and 86 nmol/liter in the groups receiving 10, 30, and 40 μg (ANOVA; P < 0.001). No hypercalcemia occurred; plasma calcium, serum PTH, and urine calcium excretion was similar between the groups. Peripheral quantitative computed tomography showed a trend toward larger tibial total bone and cortical bone area with higher vitamin D doses.

Conclusion: Vitamin D3 supplementation with up to 40 μg/d from age 2 wk to 3 months was safe and caused no hypercalcemia or hypercalciuria.
The 40-μg dose maintained S-25-OHD above 80 nmol/liter in all infants.
More extensive and longer intervention studies are necessary to assess long-term effects.

PDF is attached at the bottom of this page

See also VitaminDWiki


Attached files

ID Name Comment Uploaded Size Downloads
3304 1600 IU safe for infants.pdf PDF admin 22 Nov, 2013 15:16 520.15 Kb 832